BASF announced that it would invest $65 million to improve its PVP manufacturing facilities, as well as add production to its Shanghai facility.
BASF announced on Jan. 22, 2015 that it planned to invest up to €56 million ($65 million USD) in the expansion of its Polyvinyl pyrrolidone (PVP) value chain over the course of the next four years. PVP is a polymer used in the pharmaceutical industry because of its binding properties. The expansion will allow BASF to increase production by 6000 metric tons with improvements to facilities in Ludwigshafen, Germany and Geismar, Louisiana, USA, as well as adding the technology to produce PVP at its Shanghai, China facility.
PVP is a water-soluble polymer that can absorb large quantities of water;, it is temperature-resistant, pH-stable, non-ionic, and colorless. The binding abilities of BASF’s line of PVP products, called Kollidon, enable individual active ingredients of a tablet to form a homogenous entity and as a disintegrant it ensires ensures that the tablets break up in liquid and release the active ingredient quickly.
“With this investment, we are actively participating in the strongly growing PVP market, especially within the pharmaceutical industry,” said Saori Dubourg, president of BASF’s nutrition and health division, in a press release.
Source: BASF
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.